First Online: 8 February 2018
: J.S.S. has received grant support from and/or provided expert advice to AbbVie, Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Gilead, Glaxo, ILTOO, Janssen, Lilly, Pfizer, MSD, Roche, Samsung, Novartis-Sandoz and UCB. D.A. served as a consultant and/or speaker for AbbVie, AstraZeneca, BMS, Janssen, Medac, MSD, Pfizer, Roche and UCB and received grant support from BMS. A.B. received grants, speaker fees and/or consultancy fees from Pfizer, Eli Lilly, Janssen, Celgene, Roche-Chugai and Boehringer-Ingelheim. G.R.B. received honoraria for consulting and lectures from AbbVie, BMS, MSD, Pfizer, UCB and Roche. P.E. has undertaken clinical trials and provided expert advice to Pfizer, MSD, AbbVie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Eli Lilly. G.S.F. has received grant funding from Janssen and Gilead. A.K. has served as a consultant and/or performed clinical research for AbbVie, Amgen, Celgene, Janssen, Novartis and UCB. I.B.M. has received grants, speaker fees and/or consultancy fees from BMS, AbbVie, Pfizer, Eli Lilly, GSK, Janssen, Novartis, Celgene, Roche-Chugai, UCB and Boehringer-Ingelheim. D.H.S. serves in unpaid roles on a clinical trial sponsored by Pfizer. V.S. has served as a consultant to AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celltrion, Genentech/Roche, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sanofi and UCB and is a founding member of the executive of OMERACT (Outcome Measures in Rheumatology; 1992–present), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arm's-length funding from 36 sponsors. K.Y. received honoraria for consulting and lectures from AbbVie, AYUMI, BMS, Chugai, Eisai, Janssen, Ono, Pfizer, Tanabe-Mitsubishi and UCB.
Free to read: This content has been made available to all.